ADMA Biologics Inc (NASDAQ:ADMA) was the recipient of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 67,984 shares, a growth of 13.6% from the February 28th total of 59,836 shares. Based on an average daily trading volume, of 14,712 shares, the days-to-cover ratio is presently 4.6 days.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Spark Investment Management LLC increased its position in shares of ADMA Biologics by 24.6% in the third quarter. Spark Investment Management LLC now owns 39,000 shares of the biotechnology company’s stock valued at $282,000 after buying an additional 7,700 shares in the last quarter. Iguana Healthcare Management LLC increased its position in shares of ADMA Biologics by 20.0% in the third quarter. Iguana Healthcare Management LLC now owns 150,000 shares of the biotechnology company’s stock valued at $1,086,000 after buying an additional 25,000 shares in the last quarter. Finally, Perceptive Advisors LLC purchased a new stake in ADMA Biologics during the fourth quarter valued at approximately $3,692,000. Hedge funds and other institutional investors own 73.57% of the company’s stock.
ADMA Biologics (NASDAQ:ADMA) traded up 0.44% during mid-day trading on Thursday, hitting $4.58. The company had a trading volume of 2,423 shares. The firm’s market capitalization is $59.02 million. The company has a 50-day moving average price of $4.73 and a 200 day moving average price of $5.28. ADMA Biologics has a 12 month low of $4.34 and a 12 month high of $8.00.
Separately, Maxim Group raised ADMA Biologics from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a research note on Monday, January 23rd.
WARNING: “ADMA Biologics Inc (ADMA) Sees Significant Increase in Short Interest” was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://www.chaffeybreeze.com/2017/04/20/short-interest-in-adma-biologics-inc-adma-rises-by-13-6-updated.html.
About ADMA Biologics
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.
Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.